Centrum Onkologii Im. Prof. Franciszka Lukaszczyka W Bydgoszczy — Clinical Trial Site

140 Registered trials

48 Currently recruiting

Organisation

Centrum Onkologii Im. Prof. Franciszka Lukaszczyka W Bydgoszczy

Location

Bydgoszcz, Poland

Identifier

ORG-100007270

Address

Ul. Izabeli Romanowskiej 2, 85-796, Poland

Departments

-
2003: Ambulatorium Chemioterapii
Ambolutorium Chemioterapii
Ambulatorim Chemioterapii
Ambulatorium Chemioterapii
Ambulatorium Chemioterapi
Ambulatorium Chemioterapii
Ambulatorium Chemioterapii I
Ambulatorium Chemioterapii i Oddzial Kliniczny Radioterapii
Ambulatorium Chemioterapii i Oddział Kliniczny Radioterapii
Ambulatorium Chemoterapii
Ambulatorium Chemoterapii I
Centrum Onkologii
Centrum Onkologii im. Prof. Franciszka Lukaszczyka Ambulatorium Chemioterapii
Centrum Onkologii Im. Prof. Franciszka Łukaszczyka w Bydgoszczy
Centrum Onkologii, Ambulatorium Chemioterapii, im. Prof. Franciszka Lukaszczyka
Centrum onkologii, Medical Oncology Department
Chemotherapy outpatient clinic
Department of Chemotherapy
Dispensary of Chemotherapy
Katedra i Klinika Onkologii i Brachyterapii
n/a
NA
Oddzial Chemioterapii
Oddzial Kliniczny Brachyterapii
Oddzial‚ Kliniczny Onkologii B
Oddział Chemioterapii
Oddział Kliniczny Brachyterapii
Oddział Kliniczny Chirurgii Onkologicznej
Oddział Kliniczny Onkologii
Oddział Kliniczny Onkologii B
Oncology
Oncology department
Zakład Madycyny Nuklearnej
Zakład Medycyny Nuklearnej
Zakład Neuroonkologii i Radiochirurgii

Clinical trials at this site (140)

Search interface

A research study to investigate the safety of setanaxib and helpfulness in the treatment of recurrent or metastatic squamous cell carcinoma … Ended

2023-509917-35-00 Recurrent or Metastatic Squamous Cell Carcinoma of the 4 2022-03-21
Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal J… Ended

2023-505457-40-00 Previously Untreated Advanced Gastric or Gastroesophage 5 2022-02-02
Preoperative intraperitoneal chemotherapy in adjuvant hyperthermia adjunctive therapy in advanced gastric cancer with high-risk of peritonea… Ended

2024-516042-18-00 Gastric Carcinoma 10 2021-09-08
Study of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Given with Chemotherapy, to Treat Metastatic Squamous or Non Squamous … Ended

2023-508308-40-00 Metastatic (stage IV) squamous or nonsquamous non-small 5 2021-07-30
A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma Ended

2023-503280-42-00 Metastatic Clear Cell Renal Cell Carcinoma 5 2021-06-01
TSRO-Ph2, Dostarlimab +CT vs Pembro +CT, 1L H2H efficacy comparison in Metastatic NSCLC pts. PERLA Ended

2023-505894-33-00 Lung Cancer, Non-Small Cell 4 2020-11-25
A Study of Atezolizumab with or without Tiragolumab in Participants with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have … Ended

2022-502052-30-00 Unresectable Esophageal Squamous Cell Carcinoma 5 2020-10-27
A Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination with Cabozantinib Versus Cabozantinib Alone in Patients wit… Ended

2024-517785-42-00 Renal cell carcinoma (RCC) 5 2020-10-08
Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide plus ADT in mHSPC Ended

2023-507024-24-00 Metastatic hormone sensitive prostate cancer 5 2020-05-05
A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery Ended

2022-502886-71-00 Previously Untreated Locally Advanced Non-small Cell Lu 5 2019-11-20
Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended

2022-500785-10-00 Metastatic Castration-Resistant Prostate Cancer 5 2019-08-23
Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC Ended

2022-500413-11-00 Unresected Stage I or II Non-Small Cell Lung Cancer (NS 5 2019-06-17
A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli… Ended

2022-501970-20-01 Cis-eligible Muscle-invasive bladder cancer. 5 2019-06-07
A Phase IB Study to determine efficacy and safety of Durvalumab and/or novel anti-cancer agents, with or without chemotherapy, in patients w… Ended

2024-511956-42-00 Metastatic Non-Small Cell Lung Cancer (NSCLC) 3 2019-05-14
Study of durvalumab/placebo + chemoradiation therapy in Patients with Unresectable, Locally Advanced Non-small Cell Lung Cancer Ended

2024-515321-29-00 Patients with Locally Advanced, Unresectable Non-small 5 2018-06-26
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, … Ended

2023-509711-83-00 Advanced or Metastatic Renal Cell Carcinoma 5 2017-10-27
A Study of Nivolumab and Ipilimumab Combined with Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV … Ended

2023-508757-75-00 Stage IV Non-Small Cell Lung Cancer (NSCLC) 5 2017-09-18
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy … Ended

2022-501382-49-00 Triple Negative Breast Cancer (TNBC) 5 2017-03-07
Phase 1/2 Study of Belzutifan Plus Palbociclib Versus Belzutifan in Advanced Renal Cell Carcinoma (RCC) Ended

2023-504963-17-00 Advanced ccRCC 9
APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer) Ended

2023-506975-83-00 HER2-positive metastatic breast cancer (MBC) and early 5